[go: up one dir, main page]

ES2086536T3 - Uso de ketorolaco para el tratamiento de la enfermedad periodontal. - Google Patents

Uso de ketorolaco para el tratamiento de la enfermedad periodontal.

Info

Publication number
ES2086536T3
ES2086536T3 ES91906055T ES91906055T ES2086536T3 ES 2086536 T3 ES2086536 T3 ES 2086536T3 ES 91906055 T ES91906055 T ES 91906055T ES 91906055 T ES91906055 T ES 91906055T ES 2086536 T3 ES2086536 T3 ES 2086536T3
Authority
ES
Spain
Prior art keywords
treatment
periodontal disease
ketorolaco
ketorolac
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91906055T
Other languages
English (en)
Inventor
Gary Robert Kelm
Harvey Marvin Pickrum
Matthew Joseph Doyle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Application granted granted Critical
Publication of ES2086536T3 publication Critical patent/ES2086536T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE PARA LA PREVENCION O TRATAMIENTO DE ENFERMEDADES PERIDENTALES, COMPRENDIENDO LA ADMINISTRACION TOPICA, A LOS TEJIDOS MUCOSOS DE LA CAVIDAD ORAL, DE UN COMPUESTO QUE COMPRENDE UNA CANTIDAD SEGURA Y EFECTIVA DE QUETOROLAC.
ES91906055T 1990-03-16 1991-03-01 Uso de ketorolaco para el tratamiento de la enfermedad periodontal. Expired - Lifetime ES2086536T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49469790A 1990-03-16 1990-03-16
US65106191A 1991-02-08 1991-02-08

Publications (1)

Publication Number Publication Date
ES2086536T3 true ES2086536T3 (es) 1996-07-01

Family

ID=27051510

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91906055T Expired - Lifetime ES2086536T3 (es) 1990-03-16 1991-03-01 Uso de ketorolaco para el tratamiento de la enfermedad periodontal.

Country Status (14)

Country Link
EP (1) EP0519983B1 (es)
JP (1) JP3140050B2 (es)
AT (1) ATE137967T1 (es)
AU (1) AU661818B2 (es)
BR (1) BR9106166A (es)
CA (1) CA2077693C (es)
DE (1) DE69119588T2 (es)
DK (1) DK0519983T3 (es)
ES (1) ES2086536T3 (es)
GR (1) GR3019928T3 (es)
IE (1) IE910886A1 (es)
NZ (1) NZ237449A (es)
SG (1) SG54157A1 (es)
WO (1) WO1991013609A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464609A (en) * 1990-03-16 1995-11-07 The Procter & Gamble Company Use of ketorolac for treatment of oral diseases and conditions
US5382591A (en) * 1992-12-17 1995-01-17 Sepracor Inc. Antipyretic and analgesic methods using optically pure R-ketorolac
DE4300697C1 (de) * 1993-01-13 1994-05-19 Roemmers Sa Keterolac-Derivat mit wesentlich geringerer gastrointestinaler Reizung und Ulzeration
US5626838A (en) * 1995-03-13 1997-05-06 The Procter & Gamble Company Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
US5807541A (en) * 1996-04-22 1998-09-15 Sepracor, Inc. NSAID/fluoride periodontal compositions and methods
BRPI0302736B8 (pt) 2003-06-02 2021-05-25 Ems S/A composição farmacêutica a base de cetorolaco ou de um de seus sais farmaceuticamente aceitáveis para uso sublingual
US7732478B2 (en) 2004-01-09 2010-06-08 The Trustees Of Columbia University In The City Of New York Methods for facilitating metabolic control

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2629884A1 (de) * 1975-07-04 1977-01-20 Gaba Ag Mund- und zahnpflegemittel
US4919939A (en) * 1986-04-29 1990-04-24 Pharmetrix Corporation Periodontal disease treatment system
KR950013754B1 (ko) * 1987-09-11 1995-11-15 신텍스(미합중국)인코포레이티드 안과용 비스테로이드계 소염제제
US5032384A (en) * 1989-01-27 1991-07-16 Block Drug Company, Inc. Compositions and method for the treatment of disease

Also Published As

Publication number Publication date
CA2077693C (en) 1997-03-04
ATE137967T1 (de) 1996-06-15
NZ237449A (en) 1996-10-28
CA2077693A1 (en) 1991-09-17
IE910886A1 (en) 1991-09-25
DE69119588T2 (de) 1996-11-21
EP0519983B1 (en) 1996-05-15
SG54157A1 (en) 1998-11-16
BR9106166A (pt) 1993-03-16
EP0519983A1 (en) 1992-12-30
JPH05505400A (ja) 1993-08-12
AU7472991A (en) 1991-10-10
GR3019928T3 (en) 1996-08-31
JP3140050B2 (ja) 2001-03-05
AU661818B2 (en) 1995-08-10
DE69119588D1 (de) 1996-06-20
EP0519983A4 (en) 1993-03-10
WO1991013609A1 (en) 1991-09-19
DK0519983T3 (da) 1996-10-14

Similar Documents

Publication Publication Date Title
CA2222676A1 (en) New pharmaceutical composition with anaesthetic effect
ES2152966T3 (es) Formas de dosificado farmaceuticas de desleido rapido y procedimiento para su preparacion.
BR9106864A (pt) Composicoes de liberacao prolongada para o tratamento de doencas periodontais
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
ES2193337T3 (es) Utilizacion de sales de estroncio para el tratamiento de la artrosis.
ES482778A0 (es) Un procedimiento para la preparacion de una composicion u- til en el tratamiento de la epidermis.
ATE67085T1 (de) Mittel zur oralen hygiene.
ES2162319T3 (es) Uso del agente quelante clioquinol para la fabricacion de una composicion farmaceutica para el tratamiento de la enfermedad de alzheimer.
ES2084579T3 (es) Uso de buspirona en la preparacion de una composicion farmaceutica para el tratamiento del abuso del alcohol.
KR950702405A (ko) 구강 조성물(oral compositions)
ITRM920270A0 (it) Composizione farmaceutica per il trattamento e la prevenzione delle infiammazioni cutanee e della mucosa orale.
CO5160321A1 (es) Novedosas composiciones de tipranavir y ritonavir
ES2136167T3 (es) Composiciones de idebenona para tratar la enfermedad de alzheimer.
ES2086536T3 (es) Uso de ketorolaco para el tratamiento de la enfermedad periodontal.
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
BR9506956A (pt) Composição farmacêutica antitussígena
NO970178L (no) Terpenoidderivater (sarcodictyiner) som er nyttige som antitumormidler
BR9911005A (pt) Uso de ozÈnio para a preparação de medicamentos para o tratamento de cáries dentárias
ES2150547T3 (es) Uso de dimeticona para la fabricacion de un medicamento para el tratamiento de aftas y estomatitis.
ES2169942T3 (es) Uso de preparaciones topicas de trinitrato de glicerilo y lanolina para el tratamiento de la disfuncion erectil.
AR007059A1 (es) Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto
BR9701455A (pt) Uso de antagonistas de bradicinina para a preparaçao de medicamentos para o tratamento de doenças fibrogenéticas crônicas do fígado e doenças agudas do fígado
ITMI912466A1 (it) Uso di 1, 2 dipalmitoil-l-alfa-fosfatidil-n, n-dimetiletanolammina, in composizioni dermatologiche
DAWBER ORAL TIUSORALEN THERAPY IN VITILIGO
ES2190499T3 (es) Uso de antagonistas de bradiquinina para la preparacion de medicamentos para el tratamiento y la prevencion de la enfermedad de alzheimer.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 519983

Country of ref document: ES